COMMUNIQUÉS West-GlobeNewswire

Aphios Pharma Raising Equity Capital to Develop FDA-Approved, Cannabis-Based Drug for Opioid Addiction

08/12/2017 - 14:00

WOBURN, Mass., Dec. 08, 2017 (GLOBE NEWSWIRE) -- Aphios ® Pharma today announced plans to raise equity capital from investors to develop an FDA-approved, cannabis-based drug for treating opioid addiction, a highly unmet [...]

Stemline Therapeutics Announces Four SL-401 Presentations at Upcoming ASH Meeting

08/12/2017 - 13:00

NEW YORK, Dec. 08, 2017 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML ), a clinical-stage biopharmaceutical company developing novel therapeutics for difficult to treat cancers, announced today that SL- [...]

SteadyMed Announces FDA Agreed Pathway to Trevyent NDA Resubmission

08/12/2017 - 12:55

SAN RAMON, Calif., Dec. 08, 2017 (GLOBE NEWSWIRE) -- SteadyMed Ltd. (Nasdaq: STDY ), a specialty pharmaceutical company focused on the development of drug product candidates to treat orphan and high-value diseases with [...]

Nicotinamide Riboside Shown to Improve Mitochondrial Energy Production and Memory in Alzheimer’s Disease Research

08/12/2017 - 12:30

IRVINE, Calif., Dec. 08, 2017 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ: CDXC ), a science-based, fully integrated nutraceutical company devoted to extending human healthspan, announced today that in research [...]

OraSure Technologies Announces 2018 Annual Meeting Date

08/12/2017 - 12:00

BETHLEHEM, Pa., Dec. 08, 2017 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR ) today announced that its 2018 Annual Meeting of Stockholders is scheduled to be held at 10:00 a.m. EDT (7:00 a.m. PDT) on [...]

Veritas Hires Medical Director to Advise Physicians & Regulators on the Application of Cannevert’s Experimental Results with Cannabis to Clinical Practice & Public Policy

08/12/2017 - 09:05

VANCOUVER, British Columbia, Dec. 08, 2017 (GLOBE NEWSWIRE) -- Veritas Pharma Inc. (CSE:VRT) (OTC:VRTHF) (Frankfurt: 2VP ) , (“Veritas” or the “Company”) is pleased to announce the hiring of Dr. M. Scott Alexander as [...]

ERYTECH Reports Top-line Results of Phase 2b Study of Eryaspase for the Treatment of AML

08/12/2017 - 09:02

ERYTECH Reports Top-line Results of Phase 2b Study of Eryaspase for the Treatment of AML Conference call and webcast to take place Monday, December 11th at 10:00 a.m. EST LYON, France - December 8, 2017 - ERYTECH Pharma [...]

Photocure ASA: Landmark Blue Light Cystoscopy with Cysview® study is published in the Journal of Urology

08/12/2017 - 08:20

Oslo, Norway, December 8, 2017: Photocure ASA (Photocure, PHO: OSE), today announced that the official Journal of the American Urologic Association (AUA), the Journal of Urology, published the BLFCC Efficacy results [...]

Patient Enrolment in Phase II CIRCLE Study Evaluating THR-409 (ocriplasmin) for Non-Proliferative Diabetic Retinopathy (NPDR) Discontinued due to Slow Recruitment Rate

08/12/2017 - 07:30

Resources redirected to progress new drug candidates to clinic in H1 2018 Press release Leuven, Belgium, 8 December 2017 - ThromboGenics NV (Euronext Brussels: THR), a biotechnology company developing novel medicines [...]

Sandoz announces new Phase I data showing proposed biosimilar pegfilgrastim matches reference medicine

08/12/2017 - 07:15

Phase I study demonstrates matching pharmacokinetic (PK), pharmacodynamic (PD), safety and immunogenicity profiles of Sandoz biosimilar pegfilgrastim and reference medicine Pegfilgrastim is a long-acting version of the [...]

Aquinox Statement on FDA Advisory Committee Meeting to Discuss Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS)

08/12/2017 - 01:25

- Bone, Reproductive, and Urologic Drugs Advisory Committee Votes Unanimously in Favor of Unified IC/BPS Population for Clinical Trials - SILVER SPRING, Md., Dec. 07, 2017 (GLOBE NEWSWIRE) -- Aquinox Pharmaceuticals , [...]

Denali Therapeutics Announces Pricing of Initial Public Offering

08/12/2017 - 01:08

SOUTH SAN FRANCISCO, Calif., Dec. 07, 2017 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI ) today announced the pricing of its initial public offering of 13,888,888 shares of its common stock at a price to [...]

Radius Investigational Drug Elacestrant (RAD1901) Continues to Show Promise in Advanced ER+ / HER2- Breast Cancer at the 2017 San Antonio Breast Cancer Symposium

08/12/2017 - 00:30

-Elacestrant 400mg single agent Objective Response Rate (ORR) was 27.3% in heavily pre-treated patients with advanced ER+ breast cancer at the pre-determined study cutoff date of October 30, 2017- -Median PFS was 5.4 [...]

MediciNova Announces Positive Top-Line Results from the Clinical Trial of MN-166 (ibudilast) in ALS

08/12/2017 - 00:00

LA JOLLA, Calif., Dec. 07, 2017 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV ) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875 [...]

Mesoblast Named Global Technology Leader in Cell Therapy Industry

07/12/2017 - 23:33

NEW YORK and MELBOURNE, Australia, Dec. 07, 2017 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq: MESO ) (ASX:MSB) has been named by Frost & Sullivan as the 2017 Global Technology Leader in the Cell Therapy Industry. [...]

Skyline Medical Issues Letter to Shareholders

07/12/2017 - 23:00

MINNEAPOLIS, Dec. 07, 2017 (GLOBE NEWSWIRE) -- Skyline Medical Inc . (NASDAQ: SKLN ) (“Skyline” or the “Company”), producer of the FDA-approved STREAMWAY® System for automated, direct-to-drain medical fluid disposal, [...]

Gilead Sciences to Acquire Cell Design Labs

07/12/2017 - 23:00

– Demonstrates Gilead’s Deep Commitment to Cell Therapy – – Novel Cell Engineering Technologies with the Potential to Drive Discovery and Development of New Anti-Cancer Medicines – – Structured Buy Out to Acquire Cell [...]

National Research Corporation Declares Quarterly Dividend

07/12/2017 - 23:00

Lincoln, Nebraska, Dec. 07, 2017 (GLOBE NEWSWIRE) -- National Research Corporation (NASDAQ:NRCIA and NRCIB) today announced that its Board of Directors has declared a quarterly cash dividend of $0.10 (ten cents) per [...]

Flexion Therapeutics Enrolls First Patient in Phase 2 Pharmacokinetics and Safety Study of ZILRETTA™ (triamcinolone acetonide extended-release injectable suspension) in Bilateral Osteoarthritis of the Knee

07/12/2017 - 22:35

BURLINGTON, Mass., Dec. 07, 2017 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq: FLXN ) announced today the enrollment of the first patient in a clinical trial to evaluate the pharmacokinetics (PK) and safety of [...]